MedTrace Logo

Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor

NCT01150903 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 98832

Last updated 2021-07-19

Study results available
· View outcomes & findings →

Summary

Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years. Are men prescribed a PDE5 inhibitor for ED more likely to have a new diagnosis of underlying medical conditions compared to men of a similar age not receiving PDE5 inhibitor treatment?

Conditions

Interventions

OTHER

no intervention

non-interventional study

OTHER

no intervention

non-interventional study

Sponsors & Collaborators

  • Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2010-07-31
Completion
2010-08-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01150903 on ClinicalTrials.gov